Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 3/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | CXCR5 | P32302 | 3/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30863938 | 1.00 | MMP8 (0.47) | MMP8HDAC9CXCR5MMECYP2D6 | |
| SCHEMBL30684801 | 0.85 | MMP8 (0.41) | MMP8HDAC9CXCR5CYP2D6AKR1C1 | |
| SCHEMBL7445797 | 0.82 | MEN1 (0.45) | MMP8HDAC9CXCR5MMEPOLB | |
| SCHEMBL10427685 | 0.80 | MAPT (0.35) | MMP8HDAC9CYP2D6AKR1C1POLB | |
| SCHEMBL10999638 | 0.78 | HDAC9 (0.46) | MMP8HDAC9CXCR5MMEAKR1C1 | |
| SCHEMBL8078233 | 0.78 | NOTUM (0.45) | MMP8HDAC9POLBL3MBTL1TDP1 | |
| SCHEMBL30645248 | 0.78 | NOTUM (0.45) | MMP8HDAC9POLBL3MBTL1TDP1 | |
| SCHEMBL30147508 | 0.78 | HDAC9 (0.46) | MMP8HDAC9CXCR5MMEAKR1C1 | |
| SCHEMBL3309675 | 0.78 | BRD4 (0.50) | POLBTSHRALDH1A1 | |
| SCHEMBL27006578 | 0.78 | POLB (0.38) | MMP8HDAC9POLBL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102443316-B | curable phase change inks containing crystalline polyester | Xerox Corp. (US) Patent Dept. 020 Xerox Square 100 Clinton Avenue Rochester New (US) | 2016-02-03 | — | — | CN | claimed |
| US-8657430-B2 | Curable phase change inks containing crystalline polyesters | XEROX CORPORATION (US) | 2014-02-25 | — | — | US | claimed |
| US-8613506-B2 | — | — | 2013-12-24 | — | — | US | claimed |
| CN-102443316-A | Curable phase change inks containing crystalline polyesters | XEROX CORP | 2012-05-09 | — | — | CN | claimed |
| US-20120086761-A1 | CURABLE PHASE CHANGE INKS CONTAINING CRYSTALLINE POLYESTERS | XEROX CORPORATION (US) | 2012-04-12 | — | — | US | claimed |
| WO-2025079647-A1 | TRANSPARENTIZING AGENT, METHOD FOR PRODUCING SAME, TRANSPARENT PAPER, AND METHOD FOR PRODUCING SAME | 王子ホールディングス株式会社 | 2025-04-17 | — | — | WO | disclosed |
| US-12077611-B2 | Cyclic peptides multimers targeting α4β7 integrin | ZEALAND PHARMA A/S (DK) | 2024-09-03 | — | — | US | disclosed |
| US-20240228824-A1 | AQUEOUS COATING AGENT, ARTICLE, AND METHOD OF PRODUCING ROSIN-MODIFIED POLYESTER RESIN | HARIMA CHEMICALS, INCORPORATED (JP) | 2024-07-11 | — | — | US | disclosed |
| EP-4342956-A1 | AQUEOUS COATING AGENT, ARTICLE, AND PRODUCTION METHOD OF ROSIN-MODIFIED POLYESTER RESIN | Harima Chemicals, Incorporated (JP) | 2024-03-27 | — | — | EP | disclosed |
| CN-117677681-A | Aqueous coating agent, article, and method for producing rosin-modified polyester resin | 哈利玛化成株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20230406884-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ZEALAND PHARMA A/S (DK) | 2023-12-21 | — | — | US | disclosed |
| US-11713338-B2 | Cyclic peptides multimers targeting α-4-β-7 integrin | ZEALAND PHARMA A/S (DK) | 2023-08-01 | — | — | US | disclosed |
| WO-1994019349-A1 | XANTHINE DERIVATIVES AS ADENOSINE A1 RECEPTOR ANTAGONISTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-09-01 | — | — | WO | disclosed |
| EP-0449175-A2 | Selective adenosine receptor agents | MERRELL PHARMACEUTICALS INC. (US) | 1991-10-02 | — | — | EP | disclosed |
| US-5047534-A | Xanthine derivatives; hyupotensive agents, cardiotonic agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-09-10 | — | — | US | disclosed |
| WO-1991009840-A1 | MERCAPTOCYCLOACYL AMINOACID ENDOPEPTIDASE INHIBITORS | SCHERING CORPORATION (US) | 1991-07-11 | — | — | WO | disclosed |
| EP-0135177-B1 | BENZOCYCLOALKANE DERIVATIVES | DAIICHI SEIYAKU CO., LTD. (JP) | 1989-12-06 | — | — | EP | disclosed |
| US-4777257-A | CARDIOVASCULAR DISORDERS | DAIICHI SEIYAKU CO., LTD. (JP) | 1988-10-11 | — | — | US | disclosed |
| US-4665188-A | Certain [(1-imidazolyl)-lower-alkylene]-tetrahydronaphthalenecarboxylic acids or corresponding idan-carboxylic acids which are thromboxane A2 | DAIICHI SEIYAKU CO., LTD. (JP) | 1987-05-12 | — | — | US | disclosed |
| EP-0135177-A2 | Benzocycloalkane derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1985-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12077611-B2 | Cyclic peptides multimers targeting α4β7 integrin | ITGB7, ITGB4, ITGA4 | MMP8 605/4885HDAC9 1221/4885CXCR5 89/4885 |
| US-20230406884-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ITGB7, ITGB4, ITGA4 | MMP8 664/4885HDAC9 1590/4885CXCR5 151/4885 |
| US-11713338-B2 | Cyclic peptides multimers targeting α-4-β-7 integrin | ITGB7, ITGB4, ITGA4 | MMP8 740/4885HDAC9 1455/4885CXCR5 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.